Event and Time
Event Description
- On 19 September 2019, the Tribunal made a Community Treatment Order (CTO) for the plaintiff, requiring the administration of monthly injections of the anti-psychotic drug Paliperidone due to his diagnosed delusional disorder.
- The plaintiff sought to appeal this order through several motions, ultimately focusing on the 2020 Community Treatment Order issued on 15 September 2020, which mirrored the previous order after it expired on 18 September 2020.
- The plaintiff filed a notice of motion on 12 April 2021 seeking a stay of the 2020 Community Treatment Order.
Application and Claims
- The plaintiff claims that the 2020 Community Treatment Order infringes on his rights and that the medication affects his cognitive abilities, impeding his ability to conduct a fair appeal.
- He argues that the medication has no proven benefits and asserts that returning to a state of cognitive clarity is essential for him to effectively pursue his legal rights.
- The plaintiff seeks only to stay the medication order from the 2020 CTO and maintains that without the stay, his appeal is effectively rendered moot.
Judicial Decisions
- The court dismissed the plaintiff’s notice of motion filed on 12 April 2021.
- The plaintiff was ordered to pay the defendant’s costs related to this notice of motion.
Dispute Points and Legal Basis
Dispute Points
Plaintiff's Position:
- Asserted that he suffers cognitive impairment due to the medication, claiming it impacts his ability to engage in a fair appeal process.
- Criticized the defendant’s reliance on expert opinions as misleading and claimed he was denied proper legal representation.
- Maintained that the medication order infringed on his rights and that the risks presented by non-compliance were exaggerated.